论文部分内容阅读
随着医改的深入,激活了医药市场的快速扩容与消费升级;新一轮全球药品专利到期的高潮,给新品种的开发带来了新的契机。“开发新品种,获得好品种”成为了中国医药市场上所有企业共同的战略思考与迫切需求。而新药开发是一项开发周期长、资金投入大、不可预测因素多的系统工程,具有高风险性。因此,
With the deepening of medical reform, the rapid expansion of the pharmaceutical market and the upgrading of consumption have been activated. The climax of the new global pharmaceutical patent expiration brought new opportunities for the development of new varieties. “Developing New Varieties and Getting Good Varieties” has become a common strategic thinking and urgent need of all enterprises in China’s pharmaceutical market. However, the development of new drugs is a systematic project with long development cycle, large capital investment and unpredictable factors, which is of high risk. therefore,